Search Results

The Pontifical Academy of Sciences is proud to announce that Dr. Christina Rahm will be honored at its prestigious summit on May 29, 2024, at the Vatican. A distinguished scientist, entrepreneur, and philanthropist, Dr. Rahm has been recognized for her significant contributions to healthcare innovation and her unwavering commitment to improving global health.

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days after it was reported that he was under investigation for alleged medical insurance fraud in the country.

Ascential Medical & Life Sciences, a leader in end-to-end solutions for complex medical & life science devices that provides total commercialization services from ideation to scaled manufacturing, announced the appointment of Vinod Mirchandani as Chief Technology Officer.

Inteleos, a global non-profit healthcare certification organization, announced that its Point-of-Care Ultrasound Certification Academy launched its comprehensive Maternal Fetal Health Certification, with its new Obstetrics 2nd/3rd Trimester Clinical Certificate.

Despite an uncertain legislative path to becoming law, the BIOSECURE Act has already impacted the biopharma industry’s confidence in Chinese service providers and prompted efforts to diversify manufacturing partners.

Tiziana Life Sciences, Ltd. today announces a platform presentation titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” at the Annual Meeting of the American Academy of Neurology in Denver, Colorado.

Eli Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the activin type IIA receptor to induce weight loss and boost muscle mass.

Keymed Biosciences Inc. announced that Lei Zhang/Renchi Yang’s team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled “A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia” in the New England Journal of Medicine.

Indapta Therapeutics, Inc. announced that CEO Mark Frohlich, MD, will be giving a plenary talk today titled, “g-NK cells for the treatment of cancer and autoimmune disease” at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference.